Long COVID was diagnosed at 6 months in 19% in the molnupiravir group and 22% in the no-treatment group.
Molnupiravir tied to lower risk of long COVID in high-risk patients
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- FDA warns of false results from Cue Health COVID tests
- COVID patient testing, isolation of sick staff cut in-hospital viral spread, modeling study suggests
- TB-COVID co-infections increasingly common, tied to worse outcomes, data show
- Data: Heart-failure patients have 82% better odds of living longer if vaccinated against COVID